• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Neurology

Ticagrelor and aspirin taken post stroke may decrease the risk of recurrent stroke

byRayhan Saiani, MDandDeepti Shroff Karhade
July 15, 2020
in Neurology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Ticagrelor and aspirin taken after a mild-to-moderate acute non-cardioembolic stroke or high-risk transient ischemic attack led to a lower rate of subsequent stroke within 30 days.

2. The incidence of overall disability at 30 days did not differ between groups.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Following an acute ischemic stroke or transient ischemic attack (TIA), the risk of a subsequent ischemic stroke is estimated to be 5-10% within the first few months. A number of trials have sought to examine the role of antiplatelet agents to mitigate such a risk. Ticagrelor is a P2Y-12 inhibitor increasingly employed as part of dual antiplatelet therapy (DAPT) following myocardial infarction and coronary reperfusion. Evidence from prior subgroup analyses has suggested its potential benefit when used in combination with aspirin after an ischemic stroke. This multi-center, placebo-controlled, randomized controlled trial found use of aspirin and ticagrelor following a mild-moderate acute non-cardioembolic stroke or TIA to reduce the composite risk of stroke or death within thirty days when compared with use of aspirin alone. Such a finding provides further evidence in support of a short-term role of DAPT therapy following acute stroke, demonstrating a magnitude of benefit similarly exhibited in previous studies examining DAPT therapy within this setting. However, caution must be exercised in interpreting the study’s principal finding. The report of a reduced rate of stroke or death, while both included in the pre-defined primary outcome, fails to qualify the nearly equivalent all-cause mortality rate observed at thirty days in both groups. Differences in the presented primary outcome are explained largely by the reduced rate of ischemic stroke at 30 days. It should be noted there was no incident reduction in disability at 30 days between groups and a higher rate of severe bleeding – including rates of intracranial hemorrhage or fatal bleeding – was observed in those taking both aspirin and ticagrelor. The study may benefit from further characterization of functional outcomes to better delineate the risk, benefit profile.

Click here to read the study, published today in NEJM

Relevant Reading: Antiplatelet Therapy in Ischemic Stroke and Transient Ischemic Attack: An Overview of Major Trials and Meta-Analysis

RELATED REPORTS

Impaired lipoprotein cholesterol ratio is associated with cognitive impairment in patients with stroke

Delayed alteplase has clinical benefits in posterior circulation stroke outcomes

Direct oral anticoagulants increase bleeding risk after intracerebral hemorrhage in patients with atrial fibrillation

In-Depth [randomized controlled trial]: A total of 11,016 patients were enrolled and underwent randomization across 414 sites in twenty-eight countries from January 2018 until October 2019. Patients were eligible if they were found to have a mild-to-moderate acute noncardioembolic ischemic stroke or a high-risk TIA and were not planned for an endovascular intervention, including thrombectomy or thrombolysis. Randomization occurred within twenty-four hours of symptom onset or last known normal. Subjects were loaded and maintained on either aspirin and ticagrelor or aspirin and placebo for at least thirty days, after which antiplatelet therapy was left to the discretion of study site investigators. Follow-up data was collected at approximately five, thirty, and sixty days following randomization.  The primary-outcome event rate, defined as a composite risk of stroke or death within 30 days of follow-up, was lower in those taking aspirin and ticagrelor (5.5%) when compared to those taking aspirin alone (6.6%), (HR 0.83, 95% CI 0.71-0.96). The rate of ischemic stroke was lower in those taking aspirin and ticagrelor group (5.0% vs 6.3%, HR 0.79, 95% CI 0.68-0.93). No significant difference was seen in the rate of death (HR 1.33, 95% CI 0.81-2.19) or overall disability at 30 days (OR 0.98, 95% CI 0.89-1.07). A higher rate of severe bleeding was seen in 0.5% of those in the ticagrelor group, compared to 0.1% in those taking placebo (HR 3.99, 95% CI 1.74-9.14). Permanent discontinuation due to bleeding or dyspnea occurred in 3.8% of those in the aspirin and ticagrelor group, compared to 0.8% in those taking aspirin alone.

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: aspirinBrilintaischemic strokeTicagrelor
Previous Post

Association of rapid eye movement sleep with mortality in middle-aged and older adults

Next Post

Roflumilast effective for treatment of chronic plaque psoriasis

RelatedReports

Quick Take: Functional Outcome of Intravenous Thrombolysis in Patients With Lacunar Infarcts in the WAKE-UP Trial
Chronic Disease

Impaired lipoprotein cholesterol ratio is associated with cognitive impairment in patients with stroke

June 4, 2025
Stroke expansion following intra-arterial therapy may explain worse outcomes
Emergency

Delayed alteplase has clinical benefits in posterior circulation stroke outcomes

May 30, 2025
Use of aspirin for primary prevention linked to increased risk of intracranial hemorrhage
Cardiology

Direct oral anticoagulants increase bleeding risk after intracerebral hemorrhage in patients with atrial fibrillation

May 2, 2025
Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults
Emergency

Tenecteplase and alteplase demonstrate similar efficacy for acute ischemic stroke

March 22, 2025
Next Post
Quick Take: Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent)

Roflumilast effective for treatment of chronic plaque psoriasis

Randomized study of delayed cord clamping of 30 to 60 seconds in the larger infant born preterm

Randomized study of delayed cord clamping of 30 to 60 seconds in the larger infant born preterm

Randomized study of delayed cord clamping of 30 to 60 seconds in the larger infant born preterm

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Weighted vests and resistance training confer similar outcomes for bone density in the elderly
  • Breast cancer survivors may have a lower risk of Alzheimer’s dementia
  • Evaluating scar outcomes in pediatric burn patients following skin grafting 
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.